Minnesota Released Study on Marijuana and Autism

State officials tracked outcomes for 1,800 medical cannabis patients in a new health report.

Updated on Oct. 2, 2026 in Autism

A close-up of a small amber medicine bottle on a wooden shelf in a sterile, brightly lit clinic room. — The Minnesota Department of Health released a new study tracking health outcomes for 1,800 medical cannabis patients diagnosed with autism spectrum disorder. AI Illustration. Upload story photo >

Live Poll

Do you trust medical cannabis as an effective treatment for symptoms of autism?

Minnesota officials have released a study examining the effects of medical marijuana on patients with autism. The research highlights patient-reported outcomes regarding anxiety, sleep quality, and depression levels.

Why it matters

The findings provide state-level insight into how medical cannabis programs may impact autism symptoms in real-world settings. This analysis helps document patient experiences within existing legal frameworks.

Of 1,800 patients studied, 57 percent reported a 30 percent reduction in anxiety within four months. Furthermore, 41.3 percent reported improvements in depression, 37.3 percent in sleep quality, and 34.4 percent in fatigue.

The details

Researchers analyzed data collected through self-report surveys from patients and caregivers already enrolled in the Minnesota medical cannabis program. The study included some patients under the age of 18 and tracked how many maintained anxiety reductions over an eight-month period.

State officials published the medical marijuana study in October 2026.

Health Landscape

This study advances the analysis of medical cannabis outcomes within the Minnesota medical marijuana program. It represents a shift toward formalizing patient-reported data in states where medical cannabis access is already established as a public health policy.

Participants in the state program reported benefits ranging from reduced anxiety to improved sleep and lower fatigue levels. Families should consult their primary care providers to discuss these findings before making adjustments to their current health routines.

The takeaway

These reported improvements suggest potential therapeutic avenues that warrant further rigorous clinical examination. Readers should view these findings as patient-reported trends rather than clinical proof of efficacy.